Literature DB >> 10751477

Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study.

E Caturelli1, D A Siena, S Fusilli, M R Villani, G Schiavone, M Nardella, S Balzano, F Florio.   

Abstract

PURPOSE: To evaluate damage to cirrhotic liver tissue after transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: TACE was performed in 111 patients with HCC that involved less than 30% of the liver. Baseline liver function was evaluated with Child-Pugh scores and other indicators. Eighty-two patients had Child-Pugh class A disease, 27 had class B disease, and two had class C disease. All patients underwent chemotherapy followed by gelatin sponge particle embolization in the proper ("complete" embolization; n = 69) or right or left main ("partial" embolization; n = 42) hepatic artery. Liver function was assessed 4 months later, and 95 patients underwent a second TACE (complete embolization in 57, partial in 38). Liver function was again assessed 4 months later in 60 patients.
RESULTS: No patient died. Child-Pugh scores increased in all patients from a mean 5.96 to 6.28 (not significant) and 6.51 (P =. 05) after first and second TACEs, respectively. In patients with class A disease, scores increased from a mean 5.37 to 5.73 (P =.01) and 5.89 (P =.001) after first and second TACEs, respectively; in patients with class B disease, scores changed from a mean of 7.48 to 7.67 and 7.30 after first and second TACEs, respectively (not significant).
CONCLUSION: TACE does not induce significant long-term worsening of liver function in patients with class A or B cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751477     DOI: 10.1148/radiology.215.1.r00ap21123

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  25 in total

1.  Percutaneous transsplenic embolization of esophageal and gastrio-fundal varices in 18 patients.

Authors:  G Q Gong; X L Wang; J H Wang; Z P Yan; J M Cheng; S Qian; Y Chen
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

2.  Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.

Authors:  Abhishek Agarwal; Ajit Kumar Yadav; Ashish Kumar; Saumya Gupta; Hirenkumar Kamleshkumar Panwala; Navneet Redhu; Sudarsan Hariprasad; Piyush Ranjan; Anil Arora; Arun Gupta
Journal:  Indian J Gastroenterol       Date:  2015-05-05

3.  Complications of embolization.

Authors:  José I Bilbao; Antonio Martínez-Cuesta; Femín Urtasun; Octavio Cosín
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

Review 4.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

5.  Embolization of liver tumors: Past, present and future.

Authors:  Ashwin Rammohan; Jeswanth Sathyanesan; Sukumar Ramaswami; Anand Lakshmanan; Perumal Senthil-Kumar; Ulagendra Perumal Srinivasan; Ravi Ramasamy; Palaniappan Ravichandran
Journal:  World J Radiol       Date:  2012-09-28

6.  The Negative Effect of Preoperative Transcatheter Arterial Chemoembolization on Long-Term Outcomes for Resectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Authors:  Masataka Amisaki; Soichiro Honjo; Masaki Morimoto; Takehiko Hanaki; Yosuke Arai; Naruo Tokuyasu; Teruhisa Sakamoto; Yasufumi Ohuchi; Hiroaki Saito
Journal:  Yonago Acta Med       Date:  2016-12-26       Impact factor: 1.641

7.  Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma and coexisting hepatic cavernous hemangioma.

Authors:  Ran-Chou Chen; Jiunn-Ming Lii; Wei-Tsung Chen; Hsing-Yang Tu; Liang-Chung Chiang
Journal:  Eur Radiol       Date:  2005-12-06       Impact factor: 5.315

8.  An implantable rat liver tumor model for experimental transarterial chemoembolization therapy and its imaging features.

Authors:  Xin Li; Chuan-Sheng Zheng; Gan-Sheng Feng; Chen-Kai Zhuo; Jun-Gong Zhao; Xi Liu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

9.  Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience.

Authors:  Manon Buijs; Josephina A Vossen; Constantine Frangakis; Kelvin Hong; Christos S Georgiades; Yong Chen; Eleni Liapi; Jean-François H Geschwind
Journal:  Radiology       Date:  2008-10       Impact factor: 11.105

10.  Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study.

Authors:  Rodolfo Sacco; Marco Bertini; Pasquale Petruzzi; Michele Bertoni; Irene Bargellini; Giampaolo Bresci; Graziana Federici; Luigi Gambardella; Salvatore Metrangolo; Giuseppe Parisi; Antonio Romano; Antonio Scaramuzzino; Emanuele Tumino; Alessandro Silvestri; Emanuele Altomare; Claudio Vignali; Alfonso Capria
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.